TP53 and cancer: Across over 600 different cancer cell line models and ∼350 therapeutic compounds, there was a significant correlation between TP53 mutation status and increased resistance to the DNA DSB-inducing chemotherapeutic agents, bleomycin and doxorubicin (Figure 1B, bleomycin, P = 9.2 × 10−6, and doxorubicin, P = 1.4 × 10−5).